1. HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R‐CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY. (12th June 2019) Authors: Cottereau, A.; Vercellino, L.; Casasnovas, O.; Tilly, H.; Feugier, P.; Fruchart, C.; Roulin, L.; Oberic, L.; Pica, G.; Ribrag, V.; Abraham, J.; Simon, M.; Gonzalez, H.; Bouabdallah, R.; Fitoussi, O.; Sebban, C.; Lopez, A.; Macro, M.; Sahnes, L.; Morschhauser, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL. (June 2017) Authors: Gressin, R.; Daguindau, N.; Tempescul, A.; Moreau, A.; Carras, S.; Cartron, G.; Schmitt, A.; Houot, R.; Dartigeas, C.; Pignon, J.; Corm, S.; Bannos, A.; Mounier, C.; Dupuis, J.; Macro, M.; Fleury, J.; Jardin, F.; Karlin, L.; Damaj, G.; Feugier, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04. (23rd June 2022) Authors: Touzeau, C.; Perrrot, A.; Hulin, C.; Manier, S.; Macro, M.; Chretien, M.-L.; Karlin, L.; Decaux, O.; Jacquet, C.; Tiab, M.; Leleu, X.; Planchce, L.; Avet-Loiseau, H.; Moreau, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE. (23rd June 2022) Authors: Schavgoulidze, A.; Perrot, A.; Cazaubiel, T.; Leleu, X.; Manier, S.; Buisson, L.; Maheo, S.; Do Souto Ferreira, L.; Lannes, R.; Pavageau, L.; Hulin, C.; Marolleau, J.-P.; Voillat, L.; Belhadj, K.; Divoux, M.; Slama, B.; Brechignac, S.; Macro, M.; Stoppa, A.-M.; Sanhes, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 765 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM). (23rd June 2022) Authors: Macro, M.; Touzeau, C.; Mariette, C.; Manier, S.; Brechignac, S.; Vincent, L.; Hebraud, B.; Decaux, O.; Schulmann, S.; Lenoir, C.; Godmer, P.; Farge, A.; Peyro Saint Paul, L.; Parienti, J.-J.; Leleu, X. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 819 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE (THE INSURE STUDY). (23rd June 2022) Authors: Lee, H. C.; Ramasamy, K.; Macro, M.; Davies, F. E.; Abonour, R.; van Rhee, F.; Hungria, V. T.; Puig, N.; Ren, K.; Silar, J.; Enwemadu, V.; Cherepanov, D.; Stull, D. M.; Leleu, X. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 815 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY. (23rd June 2022) Authors: Facon, T.; Kumar, S. K.; Plesner, T.; Moreau, P.; Bahlis, N.; Goldschmidt, H.; O'Dwyer, M.; Perrot, A.; Venner, C. P.; Weisel, K.; Mace, J. R.; Raje, N.; Tiab, M.; Macro, M.; Frenzel, L.; Leleu, X.; Pei, H.; Borgsten, F.; Usmani, S. Z. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 826 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL-WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE-1 AND THE EMMY FRENCH COHORT. (23rd June 2022) Authors: Decaux, O.; Hulin, C.; Perrot, A.; Macro, M.; Frenzel, L.; Diels, J.; Perualila, N. J.; Ghilotti, F.; Haefliger, B.; Goldsztajn, E.; Vernet, S.; Thevenon, J.; Willaime, M.; Texier, N.; Schecter, J. M.; Madduri, D.; Jackson, C.; Valluri, S.; Moreau, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 795 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER. (23rd June 2022) Authors: Macro, M.; Decaux, O.; Perrot, A.; Royer, B.; Chretien, M.; Belhadj, K.; Mohty, M.; Frenzel, L.; Leleu, X.; Dib, M.; Allangba, O.; Zunic, P.; Botoc, I.; Malfuson, J.; Moreau, P.; Garlantazec, R.; Texier, N.; Germain, R.; Deal, C.; Hulin, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 846 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY. (23rd June 2022) Authors: Hulin, C.; Macro, M.; Perrot, A.; Royer, B.; Caillot, D.; Belhadj, K.; Frenzel, L.; Benramdane, R.; Demarquette, H.; Bareau, B.; Darre, S.; Calmettes, C.; Le Calloch, R.; Bouketouche, M.; Laribi, K.; Texier, N.; Willaime, M.; Deal, C.; Moreau, P.; Decaux, O. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 845 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗